Clinical trials: Hepatitis C Virus (HCV)
Hepatitis C Infection
Hepatitis C Infection in World Trade Center Responders
This study provides Hepatitis C virus screening to the members of the World Trade Center Health Program followed at the Icahn School of Medicine at Mount Sinai born during 1945-1965, and linkage to care for those found infected.
- Trial name
- NCT02982993
- Where
- United States
- Volunteers
- 3,906 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Hepatitis C
A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects
This is a phase 2, randomized, open-label study comparing the safety, antiviral activity, and pharmacokinetics of HCV-796 administered in combination with peginterferon alfa 2B (Peg-Intron) plus concomitant Rebetol vs.
- Trial name
- NCT00367887
- Testing
- Peg-Intron, REBETOL, HCV 796
- Where
- 35 sites in United States, Puerto Rico
- Volunteers
- 246 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Chronic Hepatitis C
Plasma Ribavirin Assay During Combination Therapy for Chronic Hepatitis C
Investigation of the usefullness of therapeutical drug monitoring of ribavirin for dose adaptation during combination therapy of chronic hepatitis C patients.
- Trial name
- NCT00209755
- Testing
- therapeutic drug monitoring of ribavirin and dose adaptation
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Hopital A Michallon
HIV Infections, Hepatitis C
Effects of Ribavirin on Zidovudine or Stavudine
The purpose of this study is to see how treatment of hepatitis C (HCV) patients with ribavirin (RBV) affects the anti-HIV drugs stavudine (d4T) or zidovudine (ZDV).
- Trial name
- NCT00021632
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Hepatitis C
Single and Multiple Dose Evaluation of ABT-072 and to Evaluate the Effect of Food on the Pharmacokinetics of ABT-072
To assess the safety, tolerability and pharmacokinetics of the ABT-072 tablet formulation administered as a single dose and then administered as multiple doses for 7 days.
- Trial name
- NCT00982826
- Testing
- ABT-072
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Abbott
Chronic Hepatitis C
Pioglitazone on Viral Kinetics, Cytokines and Innate Immunity in Insulin Resistant CHC GT 1 Subjects
The purpose of this study is to determine if rosiglitazone, a medicine used to treat diabetes, improves response to anti-viral treatment.
- Trial name
- NCT00926016
- Testing
- Pioglitazone (Actos)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Brooke Army Medical Center
Hepatitis C, Chronic
A Study of TMC435 in Participants With Genotype 1 Hepatitis C Virus (HCV) Infection
The purpose of this study is to evaluate the efficacy and safety of TMC435 in combination with peginterferon alfa-2b and ribavirin in chronic genotype 1 hepatitis C virus (HCV)-infected participants who are treatment-naive or…
- Trial name
- NCT01366638
- Testing
- TMC435, Peginterferon alfa-2b (pegIFN alfa-2b), Ribavirin (RBV)
- Where
- 11 sites in Japan
- Volunteers
- 79 people
- Sponsor
- Janssen Pharmaceutical K.K.
HIV, Hepatitis C
Injecting Drug Use Community Intervention Trial
The purpose of this study is to reduce the HIV/HCV incidence among the clients attending community-based methadone maintenance treatment (MMT) , and to prevent the secondary sexual transmission from HIV+ clients to their spouse…
- Conditions
- HIV, Hepatitis C, Syphilis, HSV-2
- Trial name
- NCT01108614
- Testing
- Intervention
- Where
- 5 sites in China
- Volunteers
- 12,000 people
- Sponsor
- National Center for AIDS/STD Control and Prevention, China CDC
Chronic Hepatitis C Virus
Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV
The purpose of this study is to evaluate the safety, tolerability, and antiviral efficacy of ledipasvir (LDV)/sofosbuvir (SOF) fixed-dose combination (FDC) tablets with or without ribavirin (RBV) administered for 12 and 24 weeks…
- Trial name
- NCT01701401
- Testing
- LDV/SOF, RBV
- Where
- 88 sites in United States, France and 5 more
- Volunteers
- 870 people
- Sponsor
- Gilead Sciences
Hepatitis C, Pregnancy Complications
Transmission of Chronic Hepatitis C in Pregnancy
This is a multicenter, non-comparative, observational study that will recruit women with singleton pregnancy and chronic HCV infection to determine the natural history of chronic HCV in pregnancy and the rate of vertical…
- Conditions
- Hepatitis C, Pregnancy Complications, Vertical Disease Transmission
- Trial name
- NCT03570112
- Testing
- SOF/VEL- sofosbuvir 400mg and velpatasvir 100mg
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- The Christ Hospital
This Study is to Assess Occurence of Insulin Resistance Among Hepatits C Infected Children Whether Thalassemic or Survivors of Childhood Malignancy
Insulin Resistance Among Hepatitis C Infected Children
The goal of this observational study was to study the occurrence of insulin resistance in hepatitis C virus infected children who were either thalassemic or survivors of childhood malignancy and its correlation to the HCV viral…
- Trial name
- NCT07238530
- Where
- Egypt
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Ain Shams University
Hepatitis, Chronic, Hepatitis C Virus
Phase 1 Study To Evaluate Antiviral Activity Of Small Molecule Direct Antiviral Agent At Multiple Doses In Subjects With Chronically Infected Hepatitis C Virus.
Phase 1 study in HVC (Hepatitis C Virus) infected subjects to determine pharmacokinetics, safety and efficacy in subjects with no or inadequate response to prior treatment.
- Trial name
- NCT00671671
- Testing
- Small Molecule Agent (PF-868554)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Pfizer
Hepatitis C, Chronic, Hepatitis C
SB497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adults With Thrombocytopenia Due To Hepatitis C
SB497115 is an oral agent which activates the thrombopoietin receptor and increases platelet counts in healthy volunteers. This study is examining several different doses of SB497115 as a treatment for patients with chronic…
- Conditions
- Hepatitis C, Chronic, Hepatitis C, Thrombocytopenia
- Trial name
- NCT00110799
- Testing
- SB497115
- Where
- 30 sites in United States, France and 3 more
- Volunteers
- 75 people
- Sponsor
- GlaxoSmithKline
Hepatitis
HCV Epidemiological Survey in China Rural Area
The purpose of this study is to determine whether the morbidity of hepatitis C with Chinese population.
- Trial name
- HCVES (NCT04593355)
- Where
- China
- Volunteers
- 6,068 people
- Sponsor
- The First Hospital of Jilin University
Hepatitis C
A Direct obserVed therApy vs fortNightly CollEction Study for HCV Treatment - ADVANCE HCV Study
Hepatitis C is a blood borne virus that can seriously damage the liver. An estimated 50,000 Scots have been infected with Hepatitis C virus (HCV). The main driver for spread of HCV infection is intravenous drug use.
- Trial name
- ADVANCE (NCT03236506)
- Testing
- Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet, Psychological intervention, Sofosbuvir 400 MG
- Where
- 2 sites in United Kingdom
- Volunteers
- 129 people
- Sponsor
- University of Dundee
Hepatitis C, Chronic
Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)
This study involves treatment with boceprevir or placebo in combination with pegylated interferon alfa-2b (PegIntron, PEG2b) + Ribavirin (RBV) (weight-based dosing [WBD]) in adult subjects with chronic hepatitis C (CHC) genotype…
- Trial name
- NCT00708500
- Testing
- Boceprevir (SCH 503034), Pegylated interferon alfa-2b (SCH 54031), Ribavirin (SCH 18908)
- Volunteers
- 404 people
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With Ribavirin
Substudy C: The purpose of this substudy is to determine whether Lambda combined with Ribavirin and Daclatasvir for 12 weeks is efficacious in treatment naïve subjects with genotype 1b chronic HCV infection
- Trial name
- D-LITE (NCT01795911)
- Testing
- Pegylated Interferon Lambda, Ribasphere, Daclatasvir
- Where
- United States
- Volunteers
- 165 people
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis C
Study on Chronic Hepatitis C Treatment With Interferon Alpha, Ribavirin and Amantadine in Naive Patients
Adding Amantadine to standard anti-viral treatment can improve sustained response rates in patients with chronic hepatitis C
- Trial name
- NCT00146016
- Testing
- Amantadine
- Where
- Netherlands
- Volunteers
- 390 people
- Sponsor
- UMC Utrecht
Opioid-Related Disorders, Hepatitis C (HCV)
Kentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk
This study will test the effectiveness, implementation outcomes, and cost effectiveness of a locally-tailored, health kiosk to reduce overdose, hepatitis C, and HIV risk behavior and improve linkage to care in rural Appalachia.
- Conditions
- Opioid-Related Disorders, Hepatitis C (HCV), Human Immunodeficiency Virus (HIV), Drug Overdose
- Trial name
- NCT05657106
- Testing
- Health kiosk
- Where
- United States
- Volunteers
- 752 people, healthy volunteers welcome
- Sponsor
- April M Young
Hepatitis C, Public Health
HCV RAS Testing in Public Health Programs
Successful treatment of hepatitis C has been reported to be associated with 62-84% reduction in all-cause mortality (deaths), 68-79% reduction in risk of HCC and 90% reduction in risk of liver transplantation.
- Conditions
- Hepatitis C, Public Health, Direct Acting Antiviral Agents, Resistance Associated Substitutions
- Trial name
- RAS-HCV (NCT04242433)
- Testing
- Direct Acting Antivirals
- Where
- 2 sites in India
- Volunteers
- 200 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.